跳至主要内容
临床试验/IRCT20220526054990N1
IRCT20220526054990N1已完成3 期

Evaluation of the effect of fluvoxamine in preventing neuropsychiatric symptoms of Long COVID syndrome

Artesh University of Medical Sciences0 个研究点目标入组 96 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
15 years 至 no limit(—)
性别
All

入选标准

  • Confirmed COVID infection by infectious disease specialist
  • Age over 15 years

排除标准

  • History of epilepsy
  • History of mania
  • History of depression
  • Use of other antidepressants
  • Pregnancy and lactationK
  • Kidney dysfunction
  • Liver dysfunction
  • History of cardiac arrhythmia
  • Any drug allergy to fluvoxamine, including skin allergies
  • Severe side effects of fluvoxamine, including malignant neuroleptic syndrome
  • Drug interactions with other drugs consumed by the patient

研究者

发起方
Artesh University of Medical Sciences

相似试验